Emerald Sets New Standard in APAC with Patient Engagement Award

SINGAPORE – March 12, 2026 – Emerald Clinical Trials, a global clinical research organization (CRO), has been recognized for its pioneering work in patient recruitment, securing the prestigious 2026 Asia Pacific Biopharma Excellence Award (ABEA). The company received the 'Best Clinical Trials Supplier Award: Outstanding Patient Recruitment & Engagement' at a ceremony held at the Sands Expo & Convention Centre on March 11.

This award places a spotlight on Emerald's proficiency in a critical, yet often challenging, aspect of drug development. Effective patient recruitment is the lifeblood of clinical trials, and failure in this area is a primary reason for delays that can stall the delivery of new medicines. By honoring Emerald, the ABEA highlights the company's success in connecting patients with potentially life-changing therapies across the diverse and complex Asia-Pacific (APAC) region.

"This recognition is a testament to our team's dedication to solving the most complex challenges in clinical development," said Chantal Elbayeh, Executive Director of Project Delivery at Emerald Clinical Trials, in a statement following the announcement. "By bridging the gap between innovative science and patient access, Emerald is not just facilitating trials—we are facilitating hope. This award reinforces our role at the forefront of strengthening the biopharmaceutical ecosystem and advancing the availability of breakthrough therapies for patients worldwide."

Navigating the Booming But Complex APAC Landscape

The award comes as the APAC region solidifies its position as a pivotal hub for global clinical research. Valued at over USD 17 billion, the regional market is projected to more than double by the mid-2030s, fueled by massive R&D investments, large and diverse patient populations, and increasingly supportive regulatory frameworks in countries like China, Japan, South Korea, and India.

However, this explosive growth is accompanied by significant operational hurdles. The region's vast cultural and linguistic diversity, coupled with varying regulatory requirements and healthcare infrastructures, creates a complex patchwork for CROs to navigate. Patient recruitment, in particular, remains a formidable challenge. Obstacles include a general lack of public awareness about clinical trials, strict eligibility criteria that narrow the patient pool, and logistical burdens—such as travel and time away from work—that can deter potential participants.

Against this backdrop, Emerald's award for 'Outstanding Patient Recruitment & Engagement' is particularly significant. It signals a proven ability to overcome these regional-specific barriers through sophisticated, compassionate, and effective strategies. The ABEA, which serves as an industry benchmark for excellence, recognized the company's operational prowess in ensuring that trials are not only initiated efficiently but are also populated with the right participants in a timely manner.

The 'Patient-First' Philosophy Driving Success

Emerald's success is rooted in a broader industry shift toward patient-centricity—a philosophy that moves beyond simply finding subjects for a trial and instead focuses on the patient's experience, needs, and well-being. This approach involves leveraging technology and empathy to make participation as seamless and accessible as possible.

Modern patient recruitment strategies, which Emerald has been lauded for mastering, increasingly rely on digital tools and artificial intelligence. This includes using AI-powered algorithms to analyze anonymized Electronic Health Record (EHR) data, identifying potentially eligible patients with a speed and accuracy that manual methods cannot match. Targeted digital outreach via social media and health forums allows CROs to meet patients where they are, providing clear, accessible information in their native languages.

Beyond recruitment, engagement is key to retention. The best-in-class strategies recognized by the award involve simplifying the trial process for the patient through tools like e-consent and remote screening. Furthermore, they emphasize continuous and transparent communication, ensuring participants feel valued and informed throughout their journey. By actively involving patient advocacy groups in trial design and material review, companies like Emerald ensure that protocols are not only scientifically sound but also practical and respectful of the patient's perspective. This human-centered approach is critical for building the trust needed to overcome historical hesitation and data privacy concerns.

A Competitive Edge in a Crowded Market

Winning the ABEA is more than an accolade; it is a powerful strategic advantage in the fiercely competitive APAC CRO market. Emerald operates alongside global giants such as IQVIA, Parexel, and Labcorp Drug Development, all of which have substantial footprints in the region. In this environment, demonstrated excellence in a high-stakes area like patient recruitment serves as a key differentiator.

The award provides an independent, third-party validation of Emerald's capabilities, offering assurance to its partners—which include over 160 biotech firms and 15 of the world's top 20 pharmaceutical companies. For these sponsors, partnering with a CRO that can de-risk and accelerate enrollment timelines translates directly into significant time and cost savings, potentially speeding a product's journey to market by months or even years.

This recognition strengthens Emerald’s market position, showcasing its ability to deliver results in a region critical for future pharmaceutical growth. As the industry continues to move toward more complex trial designs and targeted therapies, the ability to effectively recruit and retain specific patient populations will become an even more valuable currency.

The Power of Specialization: A Focus on Renal Research

A crucial component of Emerald's success story is its deep and specialized expertise in renal research. With a track record of recruiting over 103,000 patients for more than 100 renal clinical trials, the company has cultivated a profound understanding of the nuances of nephrology studies. This focus is supported by an internal Renal Clinical Development Advisory Board, comprised of world-renowned nephrologists and industry veterans.

This specialization is not just an academic strength; it directly fuels their award-winning recruitment strategies. Knowledge of specific conditions like Chronic Kidney Disease (CKD) or IgA nephropathy allows for the development of highly tailored and empathetic outreach. Emerald understands the unique challenges faced by renal patients, including complex comorbidities and concerns about the impact of a trial on their existing treatment. This enables them to design patient support programs and communication plans that address these specific anxieties head-on.

By building credibility and strong relationships with nephrology specialists and patient advocacy groups, Emerald has created a powerful network for recruitment. This focused approach demonstrates that in the complex world of clinical trials, deep therapeutic expertise combined with a genuine patient-first mindset is a winning formula for accelerating the development of new medicines.